Skip to main content

Table 1 Clinical characteristics of T2DM patients before and after nateglinide treatment

From: PPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms affect therapeutic efficacy of nateglinide in Chinese patients with type 2 diabetes mellitus

Parameters

Before treatment

After treatment

P values

FPG (mmol/L)

8.70 ± 2.23

6.67 ± 1.17

0.000

PPG (mmol/L)

14.26 ± 2.94

10.46 ± 1.59

0.000

FINS (mU/L)

9.26 ± 5.87

14.09 ± 13.47

0.007

PINS (mU/L)

39.33 ± 33.11

70.21 ± 52.89

0.000

HOMA-IR

3.61 ± 2.42

4.27 ± 4.28

0.246

HOMA-B

28.26 ± 16.01

60.31 ± 35.32

0.000

HbA1c (%)

8.35 ± 1.74

6.71 ± 1.00

0.000

TG (mmol/L)

2.15 ± 1.34

1.85 ± 1.10

0.002

TC (mmol/L)

4.98 ± 1.31

4.58 ± 1.08

0.001

HDL-C (mmol/L)

1.30 ± 0.42

1.49 ± 0.68

0.026

LDL-C (mmol/L)

2.82 ± 0.78

2.68 ± 0.74

0.066

  1. Abbreviations: FPG, fasting plasma glucose; PPG, postprandial plasma glucose; FINS, fasting serum insulin; PINS, postprandial serum insulin; HOMA-IR, homeostasis model assessment for insulin resistance; HOMA-B, homeostasis model assessment for beta cell function; HbA1c, hemoglobin A1c; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol
  2. Data are expressed as mean ± SD. P values are determined by the Student’s t test